Turning pipedreams into pipelines.

We're going there.

Pipeline

More than game changing.
Life changing.

The surest path to clinical, regulatory, and commercial success starts with validated biology. That’s why we’re focused on acquiring and developing product candidates that possess a clear mechanism of action and that aim to address diseases with well-understood pathophysiology and significant unmet medical need. We believe that targeting the causal biology of a disease provides the highest probability of dramatically improving the lives of patients.

With this approach, we’re building a broad and sustainable pipeline of product candidates with the potential to change the odds for patients with rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, ophthalmology, and metabolic disorders.

Rapidly Advancing Our Diversified Portfolio

Therapeutic AreaProgramsMoleculeApproachDiscoveryPreclinicalPhase 1Phase 2Phase 3Development Rights
Maternal Fetal Blood DisordersPrevention of FNAITRLYB212Anti-HPA-1a Monoclonal Antibody
Complement DysregulationRare DiseasesRLYB116C5 Inhibitor; Affibody-ABD Fusion
OphthalmologyRLYB114C5 Inhibitor; Pegylated Affibody
HematologySevere AnemiaRLYB331Matriptase-2 Inhibitor; Monoclonal Antibody
Metabolic DisordersHPPENPP1 programENPP1 Small Molecule Inhibitor
UndisclosedUndisclosedUndisclosed
FNAIT: Fetal and neonatal alloimmune thrombocytopenia;    HPA-1a: Human platelet antigen 1a;    ABD: Albumin binding domain;    HPP: Hypophosphatasia;    ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1
“Our team’s scientific expertise and extensive experience in rare disease drug development positions us to identify and execute on opportunities that other teams are unable to pursue.”
— Amanda Hayward, Ph.D., Head of Business Development

Partnerships

Finding treatments for rare disease isn’t about us. It’s about all of us.

There are thousands of rare diseases that have no effective treatment options. That’s why we’re actively working to accelerate innovation by all means possible — including acquiring and in-licensing promising product candidates and expanding our partnerships.

We’ve assembled a team with a track record of developing and commercializing therapies for patients with rare diseases. Our success has made us a partner of choice with leaders in industry and in academic clinical centers worldwide. We continue to collaborate with these experts to further our business development opportunities and expand our portfolio.

If you’re looking to accelerate the development of a product candidate that is aligned with Rallybio’s mission, please contact us at [email protected].